Moran Patrick S, Flattery Martin J, Teljeur Conor, Ryan Mairin, Smith Susan M
Health Technology Assessment, Health Information and Quality Authority, Dublin, Ireland.
Cochrane Database Syst Rev. 2013 Apr 30(4):CD009586. doi: 10.1002/14651858.CD009586.pub2.
Atrial fibrillation (AF) is the most common arrhythmia in clinical practice and is a leading cause of morbidity and mortality. Screening for AF in asymptomatic patients has been proposed as a way of reducing the burden of the disease by detecting people who would benefit from prophylactic anticoagulation therapy prior to the onset of symptoms. However, for screening to be an effective intervention it must improve the detection of AF and provide benefit for those who are detected earlier as a result of screening.
The primary objective of this review was to examine whether screening programmes increase the detection of new cases of AF compared to routine practice. The secondary objectives were to identify which combination of screening strategy and patient population is most effective, as well as assessing any safety issues associated with screening, its acceptability within the target population and the costs involved.
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) on The Cochrane Library, MEDLINE (Ovid) and EMBASE (Ovid) up to March 2012. Other relevant research databases, trials registries and websites were searched up to June 2012. Reference lists of identified studies were also searched for potentially relevant studies and we contacted corresponding authors for information about additional published or unpublished studies that may be relevant. No language restrictions were applied.
Randomised controlled trials, controlled before and after studies and interrupted time series studies comparing screening for AF with routine practice in people aged 40 years and over were eligible. Two authors (PM, CT or MF) independently selected the trials for inclusion.
Assessment of risk of bias and data extraction were performed independently by two authors (PM, CT). Odds ratios (OR) and 95% confidence intervals (CI) were used to present the results for the primary outcome, which is a dichotomous variable. Since only one included study was identified, no meta-analysis was performed.
One cluster randomised controlled trial met the inclusion criteria for this review. This study compared systematic screening (by invitation to have an electrocardiogram (ECG)) and opportunistic screening (pulse palpation during a general practitioner (GP) consultation for any reason followed by an ECG if pulse was irregular) to routine practice (normal case finding on the basis of clinical presentation) in people aged 65 years or older. The risk of bias in the included study was judged to be low.Both systematic and opportunistic screening of people over the age of 65 years are more effective than routine practice (OR 1.57, 95% CI 1.08 to 2.26 and OR 1.58, 95% CI 1.10 to 2.29, respectively). The number needed to screen in order to detect one additional case compared to routine practice was 172 (95% CI 94 to 927) for systematic screening and 167 (95% CI 92 to 806) for opportunistic screening. Both systematic and opportunistic screening were more effective in men (OR 2.68, 95% CI 1.51 to 4.76 and OR 2.33, 95% CI 1.29 to 4.19, respectively) than in women (OR 0.98, 95% CI 0.59 to 1.62 and OR 1.2, 95% CI 0.74 to 1.93, respectively). No data on the effectiveness of screening in different ethnic or socioeconomic groups were available. There were insufficient data to compare the effectiveness of screening programmes in different healthcare settings.Systematic screening was associated with a better overall uptake rate than opportunistic screening (53% versus 46%) except in the ≥ 75 years age group where uptake rates were similar (43% versus 42%). In both screening programmes men were more likely to participate than women (57% versus 50% in systematic screening, 49% versus 41% in opportunistic screening) and younger people (65 to 74 years) were more likely to participate than people aged 75 years and over (61% versus 43% systematic, 49% versus 42% opportunistic). No adverse events associated with screening were reported.The incremental cost per additional case detected by opportunistic screening was GBP 337, compared to GBP 1514 for systematic screening. All cost estimates were based on data from the single included trial, which was conducted in the UK between 2001 and 2003.
AUTHORS' CONCLUSIONS: Systematic and opportunistic screening for AF increase the rate of detection of new cases compared with routine practice. While both approaches have a comparable effect on the overall AF diagnosis rate, the cost of systematic screening is significantly more than that of opportunistic screening from the perspective of the health service provider. The lack of studies investigating the effect of screening in other health systems and younger age groups means that caution needs to be exercised in relation to the transferability of these results beyond the setting and population in which the included study was conducted.Additional research is needed to examine the effectiveness of alternative screening strategies and to investigate the effect of the intervention on the risk of stroke for screened versus non-screened populations.
心房颤动(AF)是临床实践中最常见的心律失常,也是发病和死亡的主要原因。对无症状患者进行AF筛查,旨在通过在症状出现前检测出可从预防性抗凝治疗中获益的人群,从而减轻疾病负担。然而,要使筛查成为一种有效的干预措施,必须提高AF的检出率,并为因筛查而更早被检测出的患者带来益处。
本综述的主要目的是研究与常规做法相比,筛查计划是否能提高AF新病例的检出率。次要目的是确定哪种筛查策略与患者群体的组合最为有效,同时评估与筛查相关的任何安全问题、其在目标人群中的可接受性以及所涉及的成本。
我们检索了截至2012年3月的Cochrane系统评价数据库(CENTRAL)、MEDLINE(Ovid)和EMBASE(Ovid)。截至2012年6月,还检索了其他相关研究数据库、试验注册库和网站。对已识别研究的参考文献列表也进行了检索,以查找潜在的相关研究,并联系了通讯作者,获取可能相关的其他已发表或未发表研究的信息。未设语言限制。
年龄在40岁及以上的人群中,比较AF筛查与常规做法的随机对照试验、前后对照研究和中断时间序列研究均符合要求。两位作者(PM、CT或MF)独立选择纳入试验。
两位作者(PM、CT)独立进行偏倚风险评估和数据提取。比值比(OR)和95%置信区间(CI)用于呈现主要结局的结果,该结局为二分变量。由于仅识别出一项纳入研究,因此未进行荟萃分析。
一项整群随机对照试验符合本综述的纳入标准。该研究将系统筛查(通过邀请进行心电图(ECG)检查)和机会性筛查(在全科医生(GP)会诊时因任何原因进行脉搏触诊,若脉搏不规则则随后进行ECG检查)与常规做法(根据临床表现进行常规病例发现)在65岁及以上人群中进行了比较。纳入研究中的偏倚风险被判定为低。对65岁以上人群进行系统筛查和机会性筛查均比常规做法更有效(OR分别为1.57,95%CI为1.08至2.26;OR为1.58,95%CI为1.10至2.29)。与常规做法相比,系统筛查检测出一例额外病例所需筛查的人数为172(95%CI为94至927),机会性筛查为167(95%CI为92至806)。系统筛查和机会性筛查在男性中均比女性更有效(OR分别为2.68,95%CI为1.51至4.76;OR为2.33,95%CI为1.29至4.19)(OR分别为0.98,95%CI为0.59至1.62;OR为1.2,95%CI为0.74至1.93)。没有关于不同种族或社会经济群体中筛查有效性的数据。没有足够的数据来比较不同医疗环境中筛查计划的有效性。除了在≥75岁年龄组中接受率相似(43%对42%)外,系统筛查的总体接受率高于机会性筛查(53%对46%)。在这两种筛查计划中,男性比女性更有可能参与(系统筛查中为57%对50%,机会性筛查中为49%对41%),年轻人(65至74岁)比75岁及以上的人更有可能参与(系统筛查中为61%对43%,机会性筛查中为49%对42%)。未报告与筛查相关的不良事件。机会性筛查每检测出一例额外病例的增量成本为337英镑,而系统筛查为1514英镑。所有成本估计均基于单一纳入试验的数据,该试验于2001年至2003年在英国进行。
与常规做法相比,AF的系统筛查和机会性筛查提高了新病例的检出率。虽然两种方法对总体AF诊断率的影响相当,但从卫生服务提供者的角度来看,系统筛查的成本明显高于机会性筛查。缺乏在其他卫生系统和较年轻年龄组中研究筛查效果的研究,这意味着在将这些结果推广到纳入研究所在的环境和人群之外时需要谨慎。需要进行更多研究,以检验替代筛查策略的有效性,并调查该干预措施对筛查人群与未筛查人群中风风险的影响。